
Sign up to save your podcasts
Or


In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Larry Brown, Sc.D., chief scientific officer at Noveome Biotherapeutics, to discuss ST266, a first-of-its-kind secretome therapy. This cell-free biologic is essentially a collection of proteins and other factors produced by amnion-derived epithelial cells and is being studied for necrotizing enterocolitis. Brown explains the story behind this novel therapy, the GMP manufacturing process Noveome developed to produce it, and the CMC challenges it faces from a regulatory perspective.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header
In this special edition of “Better Biopharma,” host Tyler Menichiello is joined by chief editors from across the Life Science Connect ecosystem to discuss what’s shaping the pharmaceutical industry in 2026. The editors reflect on recent developments in their respective spaces and make predictions on what the rest of the year has in store. They also highlight some exciting projects happening across their publications.
This roundtable features Katie Anderson, chief editor at Pharmaceutical Online; Jeff Buguliskis, Ph.D., deputy chief editor at Outsourced Pharma; Ben Comer, chief editor at Life Science Leader and host of The Business Of Biotech podcast; Ray Dogum, chief editor at Drug Discovery Online; Rachel Grabenhofer, chief editor at Clinical Supply Leader; Erin Harris, chief editor at Cell & Gene and host of Cell & Gene: The Podcast; Dan Schell, chief editor at Clinical Leader; and Anna Rose Welch, chief editor at Advancing RNA.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header
In this episode of "Better Biopharma," host Tyler Menichiello is joined by BioPlan Associates’ director of research, Katrina Cordovado, as well as Joshua Nelson, Ph.D., a senior material qualification specialist at Takeda, and Paul Priebe, a consultant and single-use expert, to continue their conversation from the Bioprocess Online Live event, "Closing The Adoption Gap For Advanced Single-Use Materials."
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header
In Part 2 of this conversation on “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their discussion about how upstream and downstream development teams can work together to accelerate timelines and reduce risk and bottlenecks in process development.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header
In this episode of “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their conversation about how upstream and downstream development teams can work together to accelerate timelines and reduce risks and bottlenecks in process development.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header
In this episode of “Better Biopharma,” host Tyler Menichiello speaks with Michael McCullar, Ph.D., CEO at RegCell, a cell-therapy company developing regulatory T cell (Treg) therapies for autoimmune diseases. They discuss RegCell’s origins and its disease-agnostic approach to product development, as well as the ongoing efforts to improve the commercial viability of cell therapies by reducing manufacturing costs through automation and point-of-care models.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nikolai Sopko, MD, Ph.D., chief operating officer, chief scientific officer, and director at PolarityBio, a biotech company developing SkinTE, an investigational autologous regenerative skin therapy for diabetic foot ulcers. The two discuss the challenges of scaling autologous therapy manufacturing, as well as the success PolarityBio has found in doing so through its parallel processing approach.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Richard Moroney, Ph.D., managing director at Stat Consulting. Moroney shares his thoughts on how organizations should think about and approach process control. His philosophy is one of continuous process improvement, as he believes there is "no ceiling" on quality control.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by FibroBiologics’ CEO and founder, Pete O’Heeron, and chief scientific officer, Hamid Khoja, Ph.D. They discuss the powerful but often overlooked fibroblast, a type of connective-tissue cell that has tremendous therapeutic potential, according to O’Heeron and Khoja. They explain the company’s mission to realize this therapeutic potential and make fibroblasts a mainstay in the cell therapy space, rivaling the prominence of stem cells.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Eric Doerr, a drug substance technical lead in the manufacturing science and technology (MSAT) group at Sanofi. The two discuss how the industry can support the next generation of biomanufacturing workers in North America, comparing incentives and initiatives in both the U.S. and Canada, where Doerr is based. Doerr also shares his thoughts on the need to proactively train workers in using AI to ensure that it serves as an enabling tool, rather than a disruptive force.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header
From the publisher's feed
“How can biopharma improve?” This question is the guiding ethos of the Better Biopharma podcast. Through conversations with experts across the biopharma landscape, host Tyler Menichiello…